Lilly is building a multi-engine growth machine: Alzheimer's Treatment Kisunla (Donanemab) - FDA-approved for early Alzheimer's, first proven to slow cognitive decline Represents a breakthrough in neurodegenerative disease treatment Oncology & Immunology Verzenio (breast cancer): $1.47B in Q3 2025 (+7% YoY) Jaypirca and Omvoh expanding in oncology and autoimmune markets Radiopharmaceutical investments through Point Biopharma ($1.4B acquisition) and Aktis Oncology partnership Pipeline Depth 40+ programs in Phase 2/3 across neuroscience, immunology, and cardiology Recent acquisitions: Scorpion Therapeutics, SiteOne Therapeutics, Adverum Biotechnologies Lilly isn't a one-trick pony
Addition of humic substances increased photodecomposition rates of diazepam and nordiazepam (28 and 47 h respectively)
In addition, NAD + production by the NNT enhance SIRT3-mediated deacetylation and loss of NAD + -dependent deacetylase SIRT3 increases the acetylation of IDH2 at K413 and decreases its enzymatic activity by reducing dimerization, thus regulates mitochondrial redox status and promotes cell tumorigenesis in luminal B breast cancer, 137 and B cell malignancies
Low Blood Pressure Especially if combined with other blood pressurelowering agents or if you are prone to hypotension
Kaiser Permanente: bridging the quality divide with integrated practice, group accountability, and health information technology
However, it is not currently licensed specifically for this indication in the UK
